Multiple Myeloma Research Consortium Clinical Trial Pipeline
Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk Smoldering MM 2 A Phase 1b Study of the Safety and Pharmacokinetics of MPDL3280A (Anti- PD-L1 Antibody) Alone or in Combination with Lenalidomide in Patients with Multiple Myeloma (Relapsed and Post-Autologous Stem Cell Transplantation) NCT02431208 Relapsed or Post Autologous Stem Cell Transplant (ASCT) 1b A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma NCT02316106 Smoldering MM 2 A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies NCT02336815 Quadruple Refractory MM 2b An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma NCT02375555 Newly Diagnosed MM 2a
Phase 2 Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma NCT02389517 Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant 2 A Phase 2 Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma A Phase 1b Study of SAR650984 (Anti-CD38 mab) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma A Phase 1, Dose Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma A Phase 2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies NCT02253316 Residual MM 2 NCT02332850 Relapsed/Refractory 1b NCT02223598 Relapsed/Refractory 1 NCT01084252 Relapsed/Refractory 2
Phase 1/2 Trial of MLN9708 plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma A Phase 1 Study of a Combination of a Selective Inhibitor of Nuclear Export (SINE), KPT-330 with Carfilzomib + Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone (PMD) in Subjects with Relapsed or Refractory Multiple Myeloma Phase 1/2 Trial of OSI-906 in Combination with Bortezomib for Relapsed Multiple Myeloma Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma NCT02119468 Relapsed/Refractory 1/2 NCT02199665 Relapsed/Refractory 1 NCT02103335 Relapsed/Refractory 1 NCT01672736 Relapsed/Refractory 1/2 NCT01794520 Relapsed/Refractory 1
Phase 1b Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed Multiple Myeloma Phase 1b Study Evaluating Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Receiving Bortezomib and Dexamethasone as SOC Phase 1/2b Study of the Bruton s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis ) in Relapsed or Refractory Multiple Myeloma A Phase 1b Study of SAR650984 (Anti-CD38 mab) in Combination with Lenalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma NCT01665794 Relapsed/Refractory 1b NCT01794507 Relapsed/Refractory 1b NCT01962792 Relapsed/Refractory 1/2 NCT01749969 Relapsed/Refractory 1b